Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Glutamatergic Dysfunction in Cognitive Aging: Riluzole in Mild Alzheimer's Disease

NCT01703117 is registered in ClinicalTrials.gov with Icahn School of Medicine at Mount Sinai as lead sponsor.

NCT NCT01703117
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01703117 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Glutamatergic Dysfunction in Cognitive Aging: Riluzole in Mild Alzheimer's Disease
Lead sponsor
Icahn School of Medicine at Mount Sinai
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2013
Completion date
May 26, 2020
Enrollment
50 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease